medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2006, Número 5

<< Anterior Siguiente >>

Rev Mex Oftalmol 2006; 80 (5)


Resultados visuales después de cirugía submacular en pacientes con membranas neovasculares coroideas idiopáticas

Flores-Peredo V, Rodríguez-Loaiza JL, Graue-Wiechers F

Idioma: Español
Referencias bibliográficas: 39
Paginas: 260-267
Archivo PDF: 570.17 Kb.


RESUMEN

Objetivo: Reportar el resultado visual, la tasa de recurrencia y las complicaciones de los pacientes a quienes se les realizó cirugía subretiniana como tratamiento para la neovascularización coroidea idiopática.
Métodos: Estudio no comparativo de una serie de casos de pacientes con NVC idiopática a los cuales se les realizó cirugía submacular. Se les realizó historia clínica, toma de agudeza visual, biomicrosocopia, y fluorangiografía previas a la cirugía. Se evaluaron la agudeza visual en la última visita, las complicaciones del procedimiento y la recurrencia de la neovascularización.
Resultados: Se incluyeron ocho pacientes con diagnóstico de membrana neovascular idiopática; Cinco casos mejoraron, dos se mantuvieron sin cambios y uno empeoró una línea de agudeza visual. Hasta el momento no se han presentado recurrencias. En dos ojos se presentó agujero macular después de la cirugía.
Conclusiones: La remoción quirúrgica de la neovascularización coroidea idiopática es capaz de estabilizar la agudeza visual en casos seleccionados.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986; 93:1169-1176.

  2. Bressler NM, Bressler SB, Fine SL. Age-related macular degeneration. Surv Ophthalmol 1988; 32:375-413.

  3. Cohen SY, Laroche A, Leguen Y y cols. Etiology of choroidal neovascularization in young patients. Ophthalmology 1996; 103:1241-4.

  4. Lindblom B, Andersson T. The prognosis of idiopathic choroidal neovascularization in persons younger than 50 years of age. Ophthalmology 1998; 105(10):1816-20.

  5. Submacular Surgery Trials Researh Group. Health and visionrelated quality of life among patients with neovascular ocular histoplasmosis or idiopathic choroidal neovascularization at time of enrollment in a randomized trial of submacular surgery: SST report No.5. Arch Ophthalmol 2005; 123(1):78-88.

  6. Macular Photocoagulation Study Group. Argon laser photocoagulation for idiopathic neovascularization. Results of a randomized clinical trial. Arch Ophthalmol 1983; 101:1358-61.

  7. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982; 100:912-18.

  8. Macular Photocoagulation Study Group. Krypton laser photocoagulation for idiopathic neovascular lesions. Results of a randomized clinical trial. Arch Ophthalmol 1990; 108:832-7.

  9. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Arch Ophthalmol 1991; 109:1109-1114.

  10. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal neovascular lesions in age-related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1220-31.

  11. Macular Photocoagulation Study Group. Laser photocoagulation of subfoveal recurrent neovascular lesions in age related macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1991; 109:1232-41.

  12. Torrón Fernández-Blanco C, Pérez Oliván S, Ferrer Novella E, Ruiz-Moreno O, Marcuello Melendo B, Honrubia López FM. Terapia fotodinámica en membrana neovascular subretiniana no relacionada con degeneración macular asociada a la edad o miopía patológica. Arch Soc Esp Oftalmol 2003; 78:471-476.

  13. Wai-Man C, Dennis SCL, Tak-Hung W y cols. Photodynamic therapy with verteporfin for subfoveal idiopathic choroidal neovascularization. One-year results from a prospective case series. Ophthalmology 2003; 110(12): 2395-2402.

  14. Thomas MA, Dickinson JD, Melberg NS, Ibanez HE. Visual results after surgical removal of subfoveal choroidal neovascular membranes. Ophthalmology 1994; 101(8):1384-96.

  15. Malberg NS, Thomas MA, Burgess DB. The surgical removal of subfoveal choroidal neovascularization: ingrowth site as a predictor of visual outcome. Retina; 16:190-195.

  16. Holekamp NM, Thomas MA, Dickinson JD, Valluri S. Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results. Ophthalmology 1997; 104:22-26.

  17. Thomas MA, Grand G, Williams DF y cols. Surgical management of subfoveal choroidal neovascularization. Ophthalmology 1992; 99(6):952-967.

  18. Grossniklaus HE, Gass JD. Clinicopathologic correlations of surgically excised type 1 and type 2 submacular choroidal neovascular membranes. Am J Ophthalmol 1998; 126:59-69.

  19. Submacular Surgery Trials Researh Group. Histopathologic and ultrastructural features of surgically excised subfoveal choroidal neovascular lesions. SST report No. 7. Arch Ophthalmol 2005; 123:914-921.

  20. Berglin L, Algvere P, Olivestedt G, Crafoord S, Stenkula S, Hansson LJ y cols. The Swedish national survey of surgical excision for submacular choroidal neovascularization (CNV). Acta Ophthalmol Scand 2001; 79(6): 580-4.

  21. Submacular Surgery Trials Researh Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. SST report No. 9. Arch Ophthalmol 2004; 122:1597-1611.

  22. Submacular Surgery Trials Researh Group. Surgical removal vs observation for subfoveal choroidal neovascularization, either associated with the ocular histoplasmosis syndrome or idiopathic. SST report No. 10. Arch Ophtalmol 2004; 122:1616-1628.

  23. Benson MT, Callear A, Tsaloumas M, China J, Beatty S. Surgical excision of subfoveal neovascular membranes. Eye 1998; 12:768-774.

  24. Moshfeghi DM, Kaiser PK, Grossniklaus HE y cols. Clinicopathologic study after submacular removal of choroidal neovascular membranes treated with verteporfin ocular photodynamic therapy. Am J Ophtalmol. 2003; 136(3): 5684-5.

  25. Spaide RF, Martin ML, Slakter J, Yannuzzi LA y cols. Treatment of idiopathic subfoveal choroidal neovascular lesions using photodynamic therapy with verteporfin. Am J Ophtalmol. 2002; 134(1):62-8.

  26. Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992; 99:933-43.

  27. Aiello LP, Gardner TW, King GL y cols. Diabetic retinopathy. Diabetes Care 19988; 21:143-56.

  28. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med 1971; 285:1182-6.

  29. Ferrara N, Houck K, Jakeman L, Leung DW. Molecular and biological properties of the vascular endothelial growth factor family of proteins. Endocr Rev 1992; 13:18-31.

  30. Ferrara N. Role of vascular endotelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semen Oncol 2002; 29(Suppl 16):10-4.

  31. Ishida S, Usui T y cols. VEGF 164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med 2003; 198: 1-8.

  32. Shima DT, Nishijima K, Jo N, Adamis AP. VEGF-mediated neuroprotection in ischemic retina. Invest Ophthalmol Vis Sci 2004; 45:2370.

  33. Senger DR, Connolly DT, Van de WL, Feder J, Dvorak HF. Purification and NH2-terminal amino acid sequence of guinea pig tumor-secreted vascular permeability factor. Cancer Res 1990; 50:1774-1778.

  34. Adamis AP, Shima DT. The role of vascular endothelial growth factor in ocular health and disease. Retina 2005; 25:111-118.

  35. Dvorak HF, Sioussat TM, Brown LF y cols. Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med 1991; 174:1275-1278.

  36. Ferrara N, Gerber H-P, LeCouter J. The biology of VEGF and its receptors. Nature Medicine 2003; 9 (6): 669-76.

  37. Eugene WM, Adamis A. Targeting angiogenesis, the underlying disorder in neovascular age-related macular degeneration. Can J Ophthalmol 2005: 40:352-68.

  38. Matsuda S, Gomi F, Oshima Y, Tohyama M, Tano Y. Vascular endothelial growth factor reduced and connective tissue growth factor induced by triamcinolone in ARPE19 cells under oxidative stress. Invest Ophthalmol Vis Sci 2005; 46:1062-1068.

  39. Brooks HL Jr, Caballero S Jr, Newell CK, Steinmetz RL y cols. Vitreous levels of vascular endothelial growth factor and stromal-derived factor 1 in patients with diabetic retinopathy and cystoid macular edema before and after intraocular injection of triamcionolone. Arch Ophthalmol 2004; 122(12):1801-7.




2020     |     www.medigraphic.com